课题基金 / 基金详情

TRANSFERRIN RECEPTOR 1 IS A CELLULAR RECEPTOR FOR NEW WORLD HEMORRHAGIC FEVER AR

TRANSFERRIN RECEPTOR 1 IS A CELLULAR RECEPTOR FOR NEW WORLD HEMORRHAGIC FEVER AR
转铁蛋白受体 1 是新世界出血热 AR 的细胞受体
批准号:
7715522
负责人:
Michael R. Farzan
金额:
$3.24万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-06-05 至 2009-04-30

项目摘要

项目成果

Michael R. Farzan的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. At least five arenaviruses cause viral hemorrhagic fevers in humans. Lassa virus, an Old World arenavirus, utilizes the cellular receptor alpha-dystroglycan to infect cells1. Machupo, Guanarito, Junin, and Sabia viruses are New World hemorrhagic fever viruses that do not use alpha-dystroglycan2. Here we demonstrate a specific, high-affinity association between transferrin receptor 1 (TfR1) and the entry glycoprotein (GP) of Machupo virus. Expression of human TfR1, but not human transferrin receptor 2, in hamster cell lines markedly enhanced infection of viruses pseudotyped with the GP of Machupo and Junin viruses, but not Lassa or lymphocytic choriomeningitis viruses. An anti-TfR1 antibody efficiently inhibited replication of Machupo, Guanarito, Junin, and Sabia viruses, but not that of Lassa virus. Iron depletion of culture media enhanced, and iron supplementation reduced, the efficiency of infection by Junin and Machupo but not Lassa pseudoviruses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
eCD4-mediated control of SIV infection in the brain
  • 批准号:
    10698442
  • 项目类别:
  • 资助金额:
    $91.41万
  • 财政年份:
    2023
  • 负责人:
    Michael R. Farzan
  • 依托单位:
Safe, CRISPR/Cas-free B cell editing for therapeutic applications
  • 批准号:
    10725412
  • 项目类别:
  • 资助金额:
    $22.13万
  • 财政年份:
    2023
  • 负责人:
    Michael R. Farzan
  • 依托单位:
Improving mRNA vaccines with extracellular vesicle-associated immunogens
  • 批准号:
    10573644
  • 项目类别:
  • 资助金额:
    $8.28万
  • 财政年份:
    2022
  • 负责人:
    Michael R. Farzan
  • 依托单位:
Targeting druggable coronavirus proteins
  • 批准号:
    10514326
  • 项目类别:
  • 资助金额:
    $578.68万
  • 财政年份:
    2022
  • 负责人:
    Michael R. Farzan
  • 依托单位:
海外基金